Topic: How To Invest

Power Growth Investor Hotline – Friday, June 28, 2024

Article Excerpt

RESMED INC., $191.42, is still a buy. The firm, symbol RMD on New York, helps investors tap the growing market for medical devices used to treat sleep apnea. ResMed’s CPAP (nasal continuous positive airway pressure) devices are also used to treat patients with chronic obstructive pulmonary disease as well as other respiratory conditions. The stock dropped on Monday after drugmaker ELI LILLY AND COMPANY, $900.90, (symbol LLY on New York) said it has applied for regulatory approval of its weight-loss drug Zepbound to include treatment of sleep apnea. Lilly said last Friday that Zepbound sharply reduced the restriction or blocking of air flow in patients with obesity and obstructive sleep apnea or interrupted breathing during sleep. That was based on new late-stage trial results released by Lilly and presented at the American Diabetes Association’s annual scientific conference in Orlando, Florida. All in all, though, ResMed’s outlook is still positive. The company had previously noted that many of the patients in the study still had clinically relevant…